These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37926903)

  • 1. Associations of bolus insulin injection frequency and smart pen engagement with glycaemic control in people living with type 1 diabetes.
    Hellman J; Hartvig NV; Kaas A; Møller JB; Sørensen MR; Jendle J
    Diabetes Obes Metab; 2024 Jan; 26(1):301-310. PubMed ID: 37926903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting.
    Danne TPA; Joubert M; Hartvig NV; Kaas A; Knudsen NN; Mader JK
    Diabetes Care; 2024 Jun; 47(6):995-1003. PubMed ID: 38569055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen.
    Adolfsson P; Hartvig NV; Kaas A; Møller JB; Hellman J
    Diabetes Technol Ther; 2020 Oct; 22(10):709-718. PubMed ID: 32003590
    [No Abstract]   [Full Text] [Related]  

  • 4. Smart Pen Exposes Missed Basal Insulin Injections and Reveals the Impact on Glycemic Control in Adults With Type 1 Diabetes.
    Ekberg NR; Hartvig NV; Kaas A; Møller JB; Adolfsson P
    J Diabetes Sci Technol; 2024 Jan; 18(1):66-73. PubMed ID: 35775735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Fast-Acting Insulin Aspart on Glycemic Control in Patients with Type 1 Diabetes Using Intermittent-Scanning Continuous Glucose Monitoring Within a Real-World Setting: The GoBolus Study.
    Danne T; Axel Schweitzer M; Keuthage W; Kipper S; Kretzschmar Y; Simon J; Wiedenmann T; Ziegler R
    Diabetes Technol Ther; 2021 Mar; 23(3):203-212. PubMed ID: 32924568
    [No Abstract]   [Full Text] [Related]  

  • 6. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
    Akturk HK; Snell-Bergeon JK; Rewers A; Klaff LJ; Bode BW; Peters AL; Bailey TS; Garg SK
    Diabetes Technol Ther; 2018 Oct; 20(10):639-647. PubMed ID: 30207748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes.
    Chen JW; Lauritzen T; Bojesen A; Christiansen JS
    Diabetes Obes Metab; 2006 Nov; 8(6):682-9. PubMed ID: 17026493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes.
    Beck RW; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro C; Li Z; Calhoun P
    Diabetes Technol Ther; 2022 Oct; 24(10):681-696. PubMed ID: 36173235
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucose control using fast-acting insulin aspart in a real-world setting: A 1-year, two-centre study in people with type 1 diabetes using continuous glucose monitoring.
    Billion L; Charleer S; Verbraeken L; Sterckx M; Vangelabbeek K; De Block N; Janssen C; Van Dessel K; Dirinck E; Peiffer F; Bolsens N; Mathieu C; Gillard P; De Block C
    Diabetes Obes Metab; 2021 Dec; 23(12):2716-2727. PubMed ID: 34402157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles.
    Bergenstal RM; Johnson ML; Aroda VR; Brazg RL; Dreon DM; Frias JP; Kruger DF; Molitch ME; Mullen DM; Peyrot M; Richter S; Rosenstock J; Serusclat P; Vance C; Weinstock RS; Levy BL
    J Diabetes Sci Technol; 2022 Sep; 16(5):1167-1173. PubMed ID: 34008442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
    Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
    Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.
    Andersen G; Eloy R; Famulla S; Heise T; Meiffren G; Seroussi C; Gaudier M; Mégret C; Chan YP; Soula O; Riddle M
    Diabetes Obes Metab; 2023 May; 25(5):1241-1248. PubMed ID: 36633505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent closed-loop blood glucose control for people with type 1 diabetes on multiple daily injections.
    Estremera E; Beneyto A; Cabrera A; Contreras I; Vehí J
    Comput Methods Programs Biomed; 2023 Jun; 236():107568. PubMed ID: 37137221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of intermittently scanned continuous glucose monitoring on quality of life and glycaemic control in persons with type 1 diabetes: A 12-month follow-up study in real life.
    Duarte DB; Fonseca L; Santos T; Silva VB; Puga FM; Saraiva M; Silva IL; Teixeira S; Vilaverde J; Cardoso MH
    Diabetes Metab Syndr; 2022 Jun; 16(6):102509. PubMed ID: 35598543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shining the Spotlight on Multiple Daily Insulin Therapy: Real-World Evidence of the InPen Smart Insulin Pen.
    MacLeod J; Im GH; Smith M; Vigersky RA
    Diabetes Technol Ther; 2024 Jan; 26(1):33-39. PubMed ID: 37855818
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of Connected Pen as a Diagnostic Tool to Evaluate Missed Bolus Dosing Behavior in People with Type 1 and Type 2 Diabetes.
    Edwards S; He X; Wang W; Poon JL; Meadows E; Price D; Johnson J; Wolpert H; Polonsky W
    Diabetes Technol Ther; 2022 Jan; 24(1):61-66. PubMed ID: 34524010
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of insulin degludec/aspart (twice-daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal-bolus therapy).
    Kawaguchi Y; Sawa J; Hamai C; Nishimura Y; Kumeda Y
    J Diabetes Investig; 2019 Nov; 10(6):1527-1536. PubMed ID: 30868726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
    Dieuzeide G; Chuang LM; Almaghamsi A; Zilov A; Chen JW; Lavalle-González FJ
    Prim Care Diabetes; 2014 Jul; 8(2):111-7. PubMed ID: 23953707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study protocol for optimising glycaemic control in type 1 diabetes treated with multiple daily insulin injections: intermittently scanned continuous glucose monitoring, carbohydrate counting with automated bolus calculation, or both? A randomised controlled trial.
    Secher AL; Pedersen-Bjergaard U; Svendsen OL; Gade-Rasmussen B; Almdal TP; Dørflinger L; Vistisen D; Nørgaard K
    BMJ Open; 2020 Apr; 10(4):e036474. PubMed ID: 32345699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.